Edgewise Therapeutics (EWTX) Other financing activities (2021 - 2025)

Edgewise Therapeutics has disclosed Other financing activities across 5 years of filings, most recently posting $5.9 million for Q4 2025.

• Other financing activities for Q4 2025 came in at $5.9 million, down 36.3% year-over-year; the trailing twelve-month figure through Dec 2025 was $7.8 million (down 28.49% YoY), and the FY2025 annual result was $7.8 million, down 17.69% from the prior year.
• Other financing activities came in at $5.9 million for Q4 2025 at Edgewise Therapeutics, up from $1.7 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $9.2 million in Q4 2024 to a low of -$97000.0 in Q4 2023.
• The 5-year median for Other financing activities is $169000.0 (2021), against an average of $1.6 million.
• Across the five-year window, Other financing activities surged 9603.09% in 2024 and slumped 85.23% in 2025, its largest moves.
• Edgewise Therapeutics' Other financing activities stood at $124000.0 in 2021, then plunged by 168.55% to -$85000.0 in 2022, then declined by 14.12% to -$97000.0 in 2023, then soared by 9603.09% to $9.2 million in 2024, then sank by 36.3% to $5.9 million in 2025.
• The last three Other financing activities figures came in at $5.9 million (Q4 2025), $1.7 million (Q3 2025), and $233000.0 (Q2 2025), per Business Quant data.